CAH Quote, Financials, Valuation and Earnings

Cencora has a net margin of 0.92% compared to Cardinal Health's net margin of 0.95%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 183.42%.

Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 0.79%. On the other hand Cencora has an analysts' consensus of $317.09 which suggests that it could grow by 9.26%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Cencora has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.596%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. Cencora offers a yield of 0.74% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are smaller than Cencora quarterly revenues of $75.5B. Cardinal Health's net income of $506M is lower than Cencora's net income of $717.9M. Notably, Cardinal Health's price-to-earnings ratio is 24.06x while Cencora's PE ratio is 33.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 0.18x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 0.92% compared to Cardinal Health's net margin of -45.89%. Cardinal Health's return on equity of -- beat Masimo's return on equity of -39.91%.

Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 0.79%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 17%. Given that Masimo has higher upside potential than Cardinal Health, analysts believe Masimo is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are larger than Masimo quarterly revenues of $372M. Cardinal Health's net income of $506M is higher than Masimo's net income of -$170.7M. Notably, Cardinal Health's price-to-earnings ratio is 24.06x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 4.28x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.92% compared to Cardinal Health's net margin of 1.39%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 0.79%. On the other hand McKesson has an analysts' consensus of $744.58 which suggests that it could grow by 2.82%. Given that McKesson has higher upside potential than Cardinal Health, analysts believe McKesson is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. McKesson offers a yield of 0.38% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are smaller than McKesson quarterly revenues of $90.8B. Cardinal Health's net income of $506M is lower than McKesson's net income of $1.3B. Notably, Cardinal Health's price-to-earnings ratio is 24.06x while McKesson's PE ratio is 28.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 0.92% compared to Cardinal Health's net margin of 28.26%. Cardinal Health's return on equity of -- beat ResMed's return on equity of 25.76%.

Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 0.79%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 5.09%. Given that ResMed has higher upside potential than Cardinal Health, analysts believe ResMed is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. ResMed offers a yield of 0.84% to investors and pays a quarterly dividend of $0.53 per share. Cardinal Health pays 58.57% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are larger than ResMed quarterly revenues of $1.3B. Cardinal Health's net income of $506M is higher than ResMed's net income of $365M. Notably, Cardinal Health's price-to-earnings ratio is 24.06x while ResMed's PE ratio is 28.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 7.39x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.